Session » Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy I
-
Abstract Number: 425
Efficacy, Pharmacokinetics, and Safety of Different Doses of Methotrexate in Combination With Adalimumab: Results From the Concerto Trial
-
Abstract Number: 426
Characteristics of Protocol-Specified Responders/Non-Responders Treated With Etanercept Plus Methotrexate in Period 1 of the Prize Study
-
Abstract Number: 427
US Veterans With Rheumatoid Arthritis Who Switch Among Tumor Necrosis Factor Blocking Agents Have No Additional Clinical Benefit With The Change In Therapy and Incur Higher Costs
-
Abstract Number: 433
Retrospective Analysis Of Certolizumab Pegol Use During Pregnancy: Update Of Impact On Birth Outcomes
-
Abstract Number: 434
Results Of 64 Weeks Of Treatment With An Anti-IL-17 Antibody, Ixekizumab, In Patients With Rheumatoid Arthritis In a Phase 2 Study
-
Abstract Number: 435
Final 5-Year Safety and Efficacy Results Of a Phase 3, Randomized, Placebo-Controlled Trial Of Golimumab In Methotrexate-naïve Patients With Rheumatoid Arthritis
-
Abstract Number: 437
Patterns Of Use Of Oral and Subcutaneous Methotrexate Use In Rheumatoid Arthritis Patients Enrolled In The U.S. Medicare Program
-
Abstract Number: 438
Tofacitinib, An Oral Janus Kinase Inhibitor, In A Rheumatoid Arthritis Open-Label Extension Study Following Adalimumab Therapy In A Phase 3 Randomised Clinical Trial
-
Abstract Number: 439
Tofacitinib, An Oral Janus Kinase Inhibitor: Analysis Of Gastrointestinal Adverse Events Across The Rheumatoid Arthritis Clinical Program
-
Abstract Number: 440
Cardiovascular Safety Findings In Rheumatoid Arthritis Patients Treated With Tofacitinib, A Novel, Oral Janus Kinase Inhibitor
-
Abstract Number: 442
Tolerability and Non-Serious Adverse Events In Rheumatoid Arthritis Patients Treated With Tofacitinib As Monotherapy Or In Combination Therapy
-
Abstract Number: 443
Efficacy and Safety Analyses Of Tofacitinib From Pooled Phase 2, Phase 3 and Long-Term Extension Rheumatoid Arthritis Studies: US Compared With Non-US Populations
-
Abstract Number: 444
Reversibility Of Pharmacodynamic Effects After Short- and Long-Term Treatment With Tofacitinib In Patients With Rheumatoid Arthritis
-
Abstract Number: 445
Post-Hoc Analysis Of Serious Infection Events and Selected Clinical Factors In Rheumatoid Arthritis Patients Treated With Tofacitinib
-
Abstract Number: 446
Remission Rates During Golimumab Treatment For Rheumatoid Arthritis Are Associated With Differences In Baseline Disease States Across Geographic Regions
-
Abstract Number: 447
High Levels Of Memory B CELLS ARE Associated With Response To A First ANTI-TNF Drug In Patients With Rheumatoid Arthritis
-
Abstract Number: 448
Effectiveness Of Tocilizumab In Monotherapy and In Combination With Different Synthetic Dmards: A Registry-Based Comparison Study
-
Abstract Number: 450
Tocilizumab Monotherapy Compared With Adalimumab Monotherapy In Patients With Rheumatoid Arthritis: An Evaluation Of High-Density Lipoprotein Composition
-
Abstract Number: 451
Evaluation Of Disease Activity By The Routine Assessment Of Patient Index Data 3 In Patients With Rheumatoid Arthritis Receiving Tocilizumab
-
Abstract Number: 452
What Are The Implications Of Concomitant and Pre-Medication On Infusion Reactions To Infliximab: Results From “RemiTRAC Infusion”, a Prospective Real-World Community Registry
-
Abstract Number: 453
Impact Of Inadequate Adherence On Clinical Outcomes: Results From The Biologics In Rheumatoid Arthritis Genetics and Genomics Study Syndicate Cohort
-
Abstract Number: 454
Antibody Response To Pneumococcal and Influenza Vaccination In Patients With Rheumatoid Arthritis Receiving Subcutaneous Abatacept
-
Abstract Number: 457
Pharmacodynamic Effect Of Intravenous Golimumab By Messenger Ribonucleic Acid Expression Profiling
-
Abstract Number: 458
High Levels Of Natural Killer CELLS ARE Associated With Response To Tocilizumab In Patients With Severe Rheumatoid Arthritis
-
Abstract Number: 459
Transaminase Levels and Hepatic Events Observed During Tocilizumab Treatment: Pooled Analysis Of Long-Term Clinical Trial Safety Data In Patients With Rheumatoid Arthritis
-
Abstract Number: 461
Higher TNFi Dosing Is Not Associated With More Serious Infectious Events (SIE), Elevated AST/ALT Or WBC<1.5 In The US Corrona Database
-
Abstract Number: 462
Reduced Response To Biologic Treatments in Rheumatoid Arthritis Patients Affected By Arterial Hypertension
-
Abstract Number: 463
An Indirect Comparisons Analysis Between Biologic Disease Modifiers in The Treatment Of Rheumatoid Arthritis To Evaluate For Efficacy and Safety
-
Abstract Number: 464
The Efficacy and Safety Of Tocilizumab Subcutaneous Versus Tocilizumab Intravenous, In Combination With Traditional Dmards In Patients With RA At 49 Weeks (SUMMACTA)
-
Abstract Number: 466
Biologic Monotherapy in French Rheumatoid Arthritis (RA) Patients From a Real-Life Clinical Practice Compared To Patients Treated with a Combination Therapy (Biologic + DMARD)
-
Abstract Number: 467
Adherence To Conventional Disease Modifying Anti-Rheumatic Drugs (cDMARDs) In Rheumatoid Arthritis (RA) Patients Treated In Association With a Biologic: A French Cross-Sectional Survey
-
Abstract Number: 468
The Differential Role Of T Helper Cells In The Pathogenesis and Responsiveness To Abatacept Therapy In Rheumatoid Arthritis
-
Abstract Number: 469
Anti-TNF Therapy Induces Positive Changes In The Lipoprotein Profile Of RA Patientes. Results Of a Prospective Study
-
Abstract Number: 471
Etanercept 25 Mg Once Weekly Program For Rheumatoid Arthritis, Psoriatic Arthropathy and Ankylosing Spondylitis Patients In Sustained Clinical and Radiological Remission
-
Abstract Number: 472
Clinical Efficacy Rate Of The Non-Specific Effect (the placebo effect) In The Tumour Necrosis Factor Inhibitors For Rheumatoid Arthritis Treatment After Methotrexate Failure: Meta-Analysis
-
Abstract Number: 473
Real-World Effectiveness and Safety Of Infliximab In The Treatment Of Rheumatoid Arthritis Over 5 Years: The Canadian Experience
-
Abstract Number: 474
HM-0523, a Novel Syk Inhibitor Significantly Ameliorates The Severity Of Arthritis In Rodents
-
Abstract Number: 475
Alteration Of Aortic Distensibility Within 6 Months Of Treatment In RA Patients: An Observational Comparison Of Infliximab and Synthetic Dmards
-
Abstract Number: 477
Golimumab Improves Patient-Reported Outcomes In Patients With Active Rheumatoid Arthritis
-
Abstract Number: 478
Analysis Of The JAK1 Selectivity Of GLPG0634 and Its Main Metabolite In Different Species, Healthy Volunteers and Rheumatoid Arthritis Patients
-
Abstract Number: 479
Attainment Of Remission, Functional, and Quality Of Life Improvements With Golimumab Treatment In Rheumatoid Arthritis Are Associated With Patient Expectations
-
Abstract Number: 480
Levels Of Circulating Mirnas Before and After 12 Months Therapy With Dmards In Patients With Early Rheumatoid Arthritis
-
Abstract Number: 481
Down-Titration of Biological Therapies In Rheumatoid Arthritis In Daily Clinical Practice
-
Abstract Number: 482
Methotrexate Use At Infliximab Initiation and Impact On Treatment Outcomes: An Analysis From A Canadian Registry
-
Abstract Number: 483
Adalimumab and Methotrexate Pharmacokinetics Following Combination Therapy With Different Methotrexate Doses in Methotrexate and Biologic-Naïve Rheumatoid Arthritis Patients: Concerto Study
-
Abstract Number: 484
Response To Biologic Disease-Modifying Anti-Rheumatic Drugs After Discontinuation Of Anti-Tumor Necrosis Factor Alpha Agents In Rheumatoid Arthritis Patients
-
Abstract Number: 486
Safety Of Biologic Therapy In Veterans With Rheumatoid Arthritis and Chronic Hepatitis B Infection
-
Abstract Number: 487
The Cost Savings Associated With a Departmental Etanercept Dose Reduction Pathway For Patients With Rheumatic Diseases and Maintained Low Disease Activity
-
Abstract Number: 488
The Effect Of Methotrexate On Adalimumab Pharmacokinetics: Pooled Analysis Of Adalimumab Pharmacokinetics In Patients With Rheumatoid Arthritis After Subcutaneous Administration
-
Abstract Number: 490
Does Low Disease Activity At Six Months Predict Remission At 12 Months In Rheumatoid Arthritis Patients Treated With Biologics In a Real–World Setting?
-
Abstract Number: 492
Distinction Between Glucocorticoid-Responders and Non-Responders In Rheumatoid Arthritis: A New Role For Endoplasmic Reticulum Aminopeptidase 2
-
Abstract Number: 493
A Real-World Risk Analysis Of Biological Treatment (Adalimumab and Etanercep) In Country With High Prevalence Of Tuberculosis and Hepatitis B/C
-
Abstract Number: 494
Autoantibody Profiles Predict Responsiveness To Methotrexate and Anti-TNF Therapy In Early Rheumatoid Arthritis
-
Abstract Number: 495
The Impact Of Inadequate Response To Prior Biologic Agents On Abatacept Drug Retention In Rheumatoid Arthritis Patients. A Pan-European Analysis Of RA Registries
-
Abstract Number: 496
Effectiveness Of Repeated Courses Of Rituximab In RA – Results From The Cererra Collaboration
-
Abstract Number: 497
Development Of a Novel Bispecific Therapeutic For Arthritic Diseases
-
Abstract Number: 498
A Systematic Review and Meta-Analysis Comparing Low- Versus High-Dose Rituximab For Rheumatoid Arthritis
-
Abstract Number: 499
Efficacy and Safety Of Infliximab Or Adalimumab Vs Abatacept In Patients With Rheumatoid Arthritis and An Inadequate Response To Methotrexate: Attest-Ample Network Randomized Trial